Traws Pharma Q1 2024 net loss $5.0M; cash $16.4M, extended by $14M April raise

Traws Pharma, Inc.

2024-Q1 EPS reported -$0.24 revenue$56,000

Cash $16.4M at March 31, 2024; raised $14M in April from TPAV/OrbiMed, funding into Q4 2024.
Net loss $5.0M ($0.24/shr) vs $5.8M ($0.28/shr) in Q1 2023; R&D down to $1.9M from $4.1M.
Completed acquisition of Trawsfynydd and concurrent $14M private placement in April 2024.
Initiated Phase 1 dosing for COVID candidate ratutrelvir; last dose cohort for narazaciclib done.
Plans Phase 2 for influenza and COVID in H2 2024; topline data expected H1 2025.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Traws Pharma, Inc. reported the first quarter of 2024 results: revenue fifty-six thousand dollars, net income $5.0 million, or $0.24 per share, EPS $0.24 per share.

Period: the first quarter of 2024
Revenue: fifty-six thousand dollars
Net income: $5.0 million, or $0.24 per share
EPS: $0.24 per share
Result: reported results

Exact text from the filing

Revenue was fifty-six thousand dollars for the first quarter of 2024, consistent with the same period in 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-062544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.